-+ 0.00%
-+ 0.00%
-+ 0.00%

Leerink Partners Initiates Coverage On Kazia Therapeutics with Outperform Rating, Announces Price Target of $30

Benzinga·10/20/2026 12:24:17
Listen to the news
Leerink Partners analyst Andrew Berens initiates coverage on Kazia Therapeutics (NASDAQ:KZIA) with a Outperform rating and announces Price Target of $30.